Print Friendly, PDF & Email


Sheep anti Human Glypican-3 (GPC3)


Catalogue number: X2395P

Synonyms
GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7

IsotypeIgG
Product Type Polyclonal Antibody
Units500 µg
HostSheep
Species reactivity Human
Application IHC (Paraffin)
WB
Western Blotting
Product Form
Unconjugated

Background
Glypican-3 encodes a putative extracellular proteoglycan that is inferred to play an important role in growth control in embryonic mesodermal tissues in which it is selectively expressed. It appears to form a complex with insulin-like growth factor and hence modulate IGF2 action. Glypican-3 is the human homolog of OCI-5, a GPI-linked proteoglycan first isolated from rat intestine. Originally identified as the molecular basis for Simpson-Golabi-Behmel syndrome (SGBS) also called Simpson dysmorphia syndrome (SDYS).

Immunogen
C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)

Purification Method
Total IgG

Concentration
See vial for concentration

Formulation
Provided as solution in phosphate buffered saline with 0.08% sodium azide

Functional Analysis
Immunohistochemistry

Applications
Antibody can be used for immunohistochemistry on paraffin-embedded tissues (10 µg/ml) and Western blotting (5-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.

Storage
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Ship Conditions
Ship at ambient temperature, freeze upon arrival

Product Stability
Products are stable for one year from purchase when stored properly

References
1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222. 2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230. 3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223. 4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394. 5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224. 6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906. 7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711. 8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990. 9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

Safety Datasheet(s) for this product:

Sodium Azide
/wp-content/uploads/2018/07/Antibody-SDS-with-Sodium-AzideV2.pdf

Sheep anti Human Glypican-3 (GPC3)

$254.00


Brand

Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370
Email: info@exalpha.com

Newsletter







Member